CLAUDIA CLANCY: Open Payments
NPI 1316271661 · PLANO, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$611 in 28 payments from 17 companies in 2025. Trend: 2023 $572 · 2024 $1,254 · 2025 $611
Food & beverage: $611
| Company | Payments | Amount |
|---|---|---|
| PFIZER INC. | 4 | $88 |
| ABBVIE INC. | 3 | $75 |
| Merck Sharp & Dohme LLC | 3 | $54 |
| JAZZ PHARMACEUTICALS INC. | 2 | $52 |
| Regeneron Healthcare Solutions, Inc. | 2 | $46 |
| Janssen Biotech, Inc. | 2 | $41 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $39 |
| Astellas Pharma US Inc | 2 | $38 |
| Stemline Therapeutics Inc. | 1 | $28 |
| Genmab U.S., Inc. | 1 | $26 |
Products named: EPKINLY, INLYTA, KEYTRUDA, ZEPZELCA, RYBREVANT, FRUZAQLA, Vyloy, Orserdu.
Industry payments across TX — which companies pay providers there.
